Home > Pressrelease > Diabetes Care Devices Market size to surpass $88bn by 2030

Diabetes Care Devices Market size to surpass $88bn by 2030

  • Published Date: September 20, 2022

Diabetes Care Devices Market size is anticipated to exceed USD 88 billion by 2030, according to a new research report by Global Market Insights Inc.

Increasing technological advancements in diabetes care devices to emerge as a significant growth rendering factor strengthening the market outlook. Non-invasive and minimally invasive self-monitoring devices have gained immense traction over recent years, encouraging leading product manufacturers to deliver affordable equipment capable of offering cost-effective, efficient, painless, and precise diabetes monitoring.

Rising disease prevalence in pregnant women to foster the adoption of insulin delivery devices

Insulin delivery devices are projected to exhibit a CAGR of over 10% during the forecast period. This is attributed to the increasing incidences of diabetes and associated health disorders among the geriatric population and pregnant women. The growing health awareness and the considerable rise in disease prevalence have fostered the adoption of self-monitoring and self-administration devices. Besides, the availability of these devices at affordable prices may positively influence the diabetes care devices industry landscape.

Browse key industry insights spread across 335 pages with 473 market data tables & 17 figures & charts from the report, “Diabetes Care Devices Market Size By Product (Blood Glucose Monitoring Devices {Self-Monitoring Blood Glucose Meters, Continuous Glucose Monitors, Testing Strips, Lancets}, Insulin Delivery Devices {Insulin Pumps [Tubed Pumps, Tubeless Pumps], Pens [Reusable, Disposable], Pen Needles [Standard, Safety], Syringes}), By End-Use (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers, Home Care), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:

Availability of professional medical staff to aid the growth of hospitals as a prominent end-user

Diabetes care devices market from hospital segment held over 45% of the revenue share in 2021 and is poised to record a sizeable valuation by 2030. The increasing number of patients being admitted to or undergoing treatment across hospital settings may propel market progression. Hospitals are equipped with advanced diabetes monitoring devices and proficient medical staff and healthcare professionals, making them a preferred healthcare alternative, thus driving product adoption in these establishments.

Improving healthcare infrastructure to drive product demand across the Asia Pacific

Asia Pacific diabetes care devices market is set to surpass USD 21 billion by 2030. The considerable growth in public-private investments focused on generating awareness about diabetes control and management may boost the expansion of the regional industry. The ongoing improvements in the existing healthcare infrastructure and the availability of an expansive patient pool may create new growth avenues for the industry across the Asia Pacific.

Strategic collaborations to define the competitive landscape

Major shareholders dominating the diabetes care devices industry include Abbott Laboratories, Arkray, Inc., B. Braun Melsungen AG,  Dexcom, Inc., F. Hoffmann-La Roche AG, Johnson & Johnson (Lifescan, Inc.), Medtronic PLC, Sinocare Inc., Nova Biomedical, Inc., Becton Dickinson, Ascensia Diabetes Care Holdings AG., and Company, Sanofi, Eli Lilly and Company, Insulet Corporation, Novo Nordisk, Dr. Reddy’s Laboratories (Wockhardt), Ypsomed Holding AG, Pendiq GmbH, Tandem Diabetes Care, Inc, DarioHealth Corp., Bionime Corporation

Authors: Sumant Ugalmugle, Rupali Swain